BEDFORD, Mass., Jan. 12, 2015 /PRNewswire/ -- Hologic, Inc.
(NASDAQ: HOLX) announced today preliminary revenue results for its
first fiscal quarter ended December 27, 2014.
The Company expects to report total revenues of approximately
$653 million, a 7% increase compared
to the prior year period and an 8% increase on a constant currency
basis. This exceeds the Company's previous quarterly revenue
guidance of $625-$635 million.
Preliminary revenues by business segment are:
$s in
millions
|
Preliminary
Revenue*
|
Change
(As
Reported)
|
Change
(Constant
Currency)
|
Diagnostics
|
$304
|
+6%
|
+7%
|
Breast
Health
|
$242
|
+7%
|
+8%
|
GYN
Surgical
|
$84
|
+7%
|
+8%
|
Skeletal
Health
|
$22
|
+5%
|
+6%
|
Total
|
$653
|
+7%
|
+8%
|
* Numbers in columns
do not foot due to rounding.
|
In addition, the Company announced that it voluntarily prepaid
$300 million of principal on its Term
Loan B facility in December 2014.
"Hologic posted strong organic revenue growth across the board
in the first quarter," said Steve
MacMillan, the Company's president and chief executive
officer. "This better-than-expected performance, combined
with the voluntary prepayment of debt, provide further evidence of
a turnaround that continues to build momentum. While we're
pleased with our results thus far, we're also mindful that there's
still much to do."
Hologic is providing these business updates in advance of the
Company's participation in the 33rd Annual J.P. Morgan
Healthcare Conference, which begins today. The Company has
posted its new conference presentation to the investor relations
section of its website at http://investors.hologic.com/.
The preliminary revenue results described in this press release
are estimates only and are subject to revision until the Company
reports its full financial results for the first quarter of fiscal
2015 on January 28, 2015.
About Hologic
Hologic, Inc. is a leading developer, manufacturer and supplier
of premium diagnostic products, medical imaging systems and
surgical products. The Company's core business units focus on
diagnostics, breast health, GYN surgical, and skeletal health. With
a unified suite of technologies and a robust research and
development program, Hologic is dedicated to The Science of Sure.
For more information on Hologic, visit www.hologic.com.
Forward-Looking Statements
This press release contains forward-looking information that
involves risks and uncertainties, including estimates for first
quarter revenues. These forward-looking statements are based upon
assumptions made by the Company as of the date hereof and are
subject to known and unknown risks and uncertainties that could
cause actual results to differ materially from those anticipated.
Actual results may differ from those indicated as a result of the
finalization of first quarter financial statements as well as other
risks and uncertainties, including, without limitation, the risks
and uncertainties described from time to time in the filings made
by the Company with the Securities and Exchange Commission (SEC).
The Company expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any such statements
presented herein to reflect any change in expectations or any
change in events, conditions or circumstances on which any such
statements are based. For further information regarding risks and
uncertainties associated with the Company's business, please refer
to the Company's filings with the SEC, including the Annual Report
on Form 10-K for the fiscal year ended September 27, 2014
filed by the Company with the SEC on November 20, 2014.
Contact:
Michael
Watts
Vice President,
Investor Relations and Corporate Communications
(858)
410-8588
michael.watts@hologic.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/hologic-preliminary-revenues-increased-7-to-653-million-in-the-first-quarter-of-fiscal-2015-300018721.html
SOURCE Hologic, Inc.